Sleep Disorders

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Here's some of what is coming soon to NeurologyLive® this week.

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

New trial results reveal alixorexton's significant efficacy in treating narcolepsy type 2, marking a potential breakthrough in sleep medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 26, 2025.

Dionne Morgan, MD, a sleep medicine physician at Baptist Health Miami Cardiac & Vascular Institute, provided commentary on World Narcolepsy Day, highlighting challenges in diagnosis and treatment, evolution in therapeutics, and combating comorbidities.

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.

The vice chair of neurology at West Virginia University reflected on receiving the AUPN Leadership Award, addressing challenges in academic neurology and the evolving responsibilities of vice chairs in advancing departmental goals.

A recent study reveals dual orexin receptor agonists (DORAs) show significantly lower abuse potential compared to traditional insomnia medications.

The VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the link between iRBD and neurodegeneration.

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

Here's some of what is coming soon to NeurologyLive® this week.

Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.

The decision stemmed from the DREAM study, which found that the Genio system was effective regardless of a patient’s sleeping position, which was particularly important considering patients spend on average 35% to 40% of in a supine position.

Here's some of what is coming soon to NeurologyLive® this week.

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the sleep disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on orexin receptor agonists.